Back to top
more

Veru (VERU)

(Real Time Quote from BATS)

$0.80 USD

0.80
180,191

-0.02 (-1.84%)

Updated Aug 30, 2024 12:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Asensus Surgical (ASXC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 25.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Veru Inc. (VERU): Can Its 39.5% Jump Turn into More Strength?

by Zacks Equity Research

Veru Inc. (VERU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Akerna Corp. (KERN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Akerna Corp. (KERN) delivered earnings and revenue surprises of -16.67% and 13.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Lags Q2 Earnings Estimates

by Zacks Equity Research

Perrigo (PRGO) delivered earnings and revenue surprises of -2.27% and 5.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Envista (NVST) Q2 Earnings Top Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 4.35% and 1.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Veru Inc. (VERU) closed at $12.10, marking a -0.9% move from the previous day.

Biotech Stock Roundup: ICPT's Study Data, NVAX Vaccine Gets EUA, VERU Up on Data

by Zacks Equity Research

Regulatory and other updates from Intercept (ICPT) and VERU are a few key highlights from the biotech sector during the past week.

Veru Inc. (VERU) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Veru Inc. (VERU) closed at $15, marking a -1.96% move from the previous day.

VERU's Shares Jump on Successful COVID-19 Study Results

by Zacks Equity Research

VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.

Veru Inc. (VERU) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Veru Inc. (VERU) closed the most recent trading day at $11.30, moving -1.31% from the previous trading session.

Veru Inc. (VERU) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Veru Inc. (VERU) closed at $13.54 in the latest trading session, marking a +1.12% move from the prior day.

Meridian Bioscience (VIVO) Moves 5.7% Higher: Will This Strength Last?

by Zacks Equity Research

Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Veru Inc. (VERU) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -12.50% and 14.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 26.87% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Stock Moves -1.8%: What You Should Know

by Zacks Equity Research

In the latest trading session, Veru Inc. (VERU) closed at $9.25, marking a -1.8% move from the previous day.

Earnings Preview: Veru Inc. (VERU) Q2 Earnings Expected to Decline

by Zacks Equity Research

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's What Could Help Veru Inc. (VERU) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Veru Inc. (VERU) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Veru Inc. (VERU) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of 27.27% and 17.99%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Can Veru Inc. (VERU) Climb 344% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 343.6% upside potential for Veru Inc. (VERU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Earnings Preview: Veru Inc. (VERU) Q1 Earnings Expected to Decline

by Zacks Equity Research

Veru Inc. (VERU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Veru (VERU) Up on FDA's Fast Track Tag for Breast Cancer Drug

by Zacks Equity Research

The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.

OrganiGram (OGI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 3.44%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of 37.50% and 14.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?